Last reviewed 2026-05-23 · How we verify

RE002 T cell

Henan Cancer Hospital · Phase 1 active Biologic ✓ Verified May 2026 Quality 0/100

RE002 T cell is a Biologic drug developed by Henan Cancer Hospital. It is currently in Phase 1 development.

RE002 T cell is being studied in a clinical trial for the treatment of KRAS G12D mutated solid tumors. The mechanism of RE002 T cell is currently unknown.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	RE002 T cell
Sponsor	Henan Cancer Hospital
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RE002 T cell CI brief — competitive landscape report
RE002 T cell updates RSS · CI watch RSS
Henan Cancer Hospital portfolio CI

Frequently asked questions about RE002 T cell

What is RE002 T cell?

RE002 T cell is a Biologic drug developed by Henan Cancer Hospital.

Who makes RE002 T cell?

RE002 T cell is developed by Henan Cancer Hospital (see full Henan Cancer Hospital pipeline at /company/henan-cancer-hospital).

What development phase is RE002 T cell in?

RE002 T cell is in Phase 1.

Manufacturer: Henan Cancer Hospital — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing